Navigation Links
China Cord Blood Corporation Files Its Annual Report on Form 20-F
Date:9/28/2011

HONG KONG, Sept. 28, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company has filed with the U.S. Securities and Exchange Commission its Annual Report on Form 20-F, which included audited financial statements for the fiscal year ended March 31, 2011.  The Form 20-F can be accessed by visiting the U.S. Securities and Exchange Commission's website at www.sec.gov and can also be found at the Investor Relations Section of CCBC's website at http://ir.chinacordbloodcorp.com.  CCBC will provide a hard copy of the Annual Report, including a complete set of audited financial statements, free of charge to its shareholders upon request.

About China Cord Blood CorporationChina Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.  For more information, please visit our website at http://www.chinacordbloodcorp.com.  

Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. For more information, please contact:China Cord Blood CorporationMs. Joeling LawTel: (+852) 3605-8180Email: ir@chinacordbloodcorp.com ICR, Inc.In New York: Ashley Ammon De Simone: 1-646-277-1227In Beijing: Wen Lei Zheng: +86-10-6583-7510
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. China Medicine Announces Strong Second Quarter 2008 Results
7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
8. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
9. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. China Biologic Products Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 2016 , ... American Process, Inc. (API) announced that the ... 9,322,133 and 9,322,134, to API and its affiliated companies for BioPlus® nanocellulose technology. ... compositions. In addition to these patents and U.S. Patent No. 9,187,865 awarded ...
(Date:5/4/2016)... (PRWEB) , ... May 05, 2016 , ... ... is proud to support the National Stroke Association during National Stroke Awareness Month ... association’s Facebook and Twitter pages throughout the month. CereScan will donate $1 ...
(Date:5/4/2016)... May 4, 2016  Bayer today announced that ... Stivarga ® (regorafenib) tablets for the treatment ... met its primary endpoint of a statistically significant ... evaluated the efficacy and safety of regorafenib in ... treatment with sorafenib. The safety and tolerability were ...
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased ... Sales. , Doug began his career at PBI-Gordon in February 1988, after finishing ... wide variety of roles, ranging from customer service to national product manager, to helping ...
Breaking Biology Technology:
(Date:3/14/2016)... 14, 2016 http://www.apimages.com ) ... --> - Renvoi : image disponible via AP ... --> --> DERMALOG, le leader ... nouveaux lecteurs d,empreintes digitales pour l,enregistrement des réfugiés ... utilisé pour produire des cartes d,identité aux réfugiés. ...
(Date:3/10/2016)... 10, 2016   Unisys Corporation (NYSE: UIS ... (CBP) is testing its biometric identity solution at the ... to help identify certain non-U.S. citizens leaving the country. ... designed to help determine the efficiency and accuracy of using ... and will run until May 2016. --> ...
(Date:3/8/2016)... , March 8, 2016   Valencell , ... today announced it has secured $11M in Series ... Tech, a new venture fund being launched by ... participation from existing investors TDF Ventures and WSJ ... to continue its triple-digit growth and accelerate its ...
Breaking Biology News(10 mins):